Hong Kong halts Pfizer/BioNTech COVID-19 vaccines, investigates defective packaging By Reuters


© Reuters. FILE PHOTO: A vial of Pfizer’s COVID-19 vaccine that received emergency use authorization is seen at George Washington University Hospital in Washington

By Farah Master

HONG KONG (Reuters) – Hong Kong on Wednesday temporarily suspended COVID-19 vaccinations using two batches of the treatment developed by Pfizer (NYSE:) and BioNTech citing defective packaging, but the government said manufacturers indicated they had no reason to believe safety was at risk, and the move was merely a preventative measure.

The government said it had received notice from Fosun Pharma Industrial (Hong Kong), the distributor of the Pfizer/BioNTech vaccine in the financial hub and in Macau, that packaging defects had been detected in a vaccine batch – numbered 210102 – related to the closure of bottles.

“BioNTech and Fosun Pharma have not found any reason to believe that product safety is at risk,” the government said. It wasn’t immediately clear how many shots would be affected, but it said use of batch 210102 would be suspended, as would that of another batch, numbered 210104, until further notice.

Fosun Pharma didn’t immediately respond to requests for comment.

On Wednesday, several centres around the Asian financial hub were told by city authorities to stop using the Pfizer/BioNTech vaccine, according to notices seen by residents.

The city began vaccinating residents with doses from China’s Sinovac Biotech Ltd in February, and began offering the Pfizer/BioNTech vaccine in March.

Macau’s Department of Health said on Wednesday it was suspending production of the BioNTech vaccine in the neighbouring special administrative region after discovering a packaging flaw.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Read More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *